AEON Biopharma, Inc.
AEON
$0.76
-$0.06-7.28%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.73% | -36.46% | -41.17% | -31.06% | -23.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.94% | -59.16% | -57.36% | -47.34% | -40.18% |
| Operating Income | 49.94% | 59.16% | 57.36% | 47.34% | 40.18% |
| Income Before Tax | -100.02% | 99.46% | 134.87% | 110.92% | 103.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.02% | 99.46% | 134.87% | 110.92% | 103.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.02% | 99.46% | 134.87% | 110.92% | 103.48% |
| EBIT | 49.94% | 59.16% | 57.36% | 47.34% | 40.18% |
| EBITDA | 50.04% | 59.26% | 57.46% | 47.43% | 40.24% |
| EPS Basic | -64.04% | 98.40% | 144.28% | 115.05% | 103.32% |
| Normalized Basic EPS | 93.60% | 90.41% | 92.42% | -75.82% | -67.45% |
| EPS Diluted | -66.12% | 98.32% | 144.24% | 114.99% | 103.32% |
| Normalized Diluted EPS | 93.62% | 90.42% | 92.43% | -75.79% | -67.45% |
| Average Basic Shares Outstanding | 1,184.26% | 570.70% | 48.09% | -58.52% | -67.95% |
| Average Diluted Shares Outstanding | 1,184.31% | 570.74% | 48.11% | -58.51% | -67.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |